КЛИВЛЕНД Шон Мэттью (GB),САЛОМОН Стефан (GB),ВАН КРИНКС Кассандра (GB)
申请号：
RU2015110027
公开号：
RU2015110027A
申请日:
2013.08.21
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A composition comprising a mesylate camostat and a single variable domain. 2. The composition of claim 1, wherein the composition is a pharmaceutical composition. A composition according to claim 1 or 2, wherein the composition should be administered orally. The composition of claim 1, wherein the single variable domain is a target-blocking single variable domain, wherein the target is TNFα, IL-23, LAG-3, IL-6, IL-13, IL-18, TSLP, CD3, any receptor of the above or ELR receptor. 5. The composition of claim 1, wherein the single variable domain neutralizes TNFα, IL-23, LAG-3, IL-6, IL-13, IL-18, TSLP or CD3.6. The composition of claim 1, wherein the single variable domain has a transition point (Tm) greater than or equal to 66 ° C. 7. The composition of claim 1, wherein the ratio of a single variable domain to a camostat mesylate is approximately 1: 0.1, 1: 1, 1:10, 1:25, 1:50, or 1: 100.8. The composition of claim 1, wherein the composition is enteric coated. The composition of claim 1 for use as a medicine. 10. The composition of claim 9, wherein the drug is intended to treat the gastrointestinal tract. The composition of claim 10, wherein the disease of the gastrointestinal tract is Crohn’s disease, colitis, including ulcerative colitis, celiac disease, Behcet syndrome and mucositis of the oral mucosa. Use of a composition according to any one of the preceding claims for the manufacture of a medicament. The use of claim 12, wherein the drug is intended to treat the gastrointestinal tract. The use of claim 13, wherein the disease of the gastrointestinal tract is Crohn’s disease, colitis, including ulcerative colitis, celiac disease, Behcet’s syndrome and mucositis of the oral mucosa. A method of treating a disease of the gastrointestinal tract, comprising the stage1. Композиция, включающая камостат мезилат и единичный вариабельный домен.2. Композиция по п. 1, где композиция представляет собой фармацевтическую композицию.3. Композиция по п. 1 или 2, где композицию
